Cynomolgus Monkey EEG Power Spectral Data for TAK-071 Study

Cynomolgus monkeys were used to study quantitative electroencephalography (qEEG) power band changes induced by scopolamine and the effects of the M1 receptor modulator TAK-071. The dataset contains measurements of theta, delta, and alpha power bands under various drug administration conditions, including scopolamine, TAK-071, donepezil, and xanomeline. The research was conducted by Emi Kurimoto and published in 2020 to identify translational biomarkers for cognitive drug evaluation.

Use Cases

• Analyze scopolamine-induced changes in theta, delta, and alpha power bands to model dose-dependent effects in non-human primates.
• Compare the efficacy of TAK-071 against donepezil and xanomeline in suppressing scopolamine-induced qEEG spectral changes.
• Investigate theta and delta power bands as potential translational biomarkers for cholinergic drug effects in preclinical studies.

Strengths

• Data is derived from a controlled pharmacological study with specific drug doses (e.g., scopolamine 25–100 μg/kg, TAK-071 0.3–3 mg/kg) documented.
• Focuses on specific, clinically-relevant qEEG power bands (theta, delta, alpha) as translational biomarkers.
• Dataset is openly available under a CC0 1.0 public domain license, facilitating unrestricted reuse.

Limitations

• Dataset size, including the number of subjects (monkeys) and measurement rows, is not specified.
• Geographic and demographic scope is limited to a single primate species (cynomolgus monkeys) in a laboratory setting.
• Data is from a 2020 publication and may not reflect the latest research findings or methodologies.

Provenance

Source

Dryad digital repository.

Collection Method

Experimental data from quantitative electroencephalography (qEEG) recordings on cynomolgus monkeys under pharmacological challenge.

Freshness

Last updated in 2020.

Geography

Laboratory study on cynomolgus monkeys; specific location not stated.